Stand Up Therapeutics signed with VectorBuilder for world’s first gene therapy supply for paraplegia patient
July 25, 2022, VectorBuilder Inc. – VectorBuilder is the world’s largest supplier of customized vectors for viral and non-viral gene delivery, operating as a multinational corporation headquartered in Chicago, USA with offices in North America, Europe, China, Japan, Korea, Australia and Israel. Currently, more than 80,000 custom vectors are produced annually for numerous researchers around the world. VectorBuilder has GMP facilities for gene delivery systems, and supplies gene therapy products and delivery systems for thousands of institutions around the world and more than 50,000 customers, including all the leading pharmaceutical companies and major universities. We are supplying gene therapy products and delivery systems.
According to Stand Up Therapeutics, through this agreement, VectorBuilder will produce and supply gene therapy products designed by Stand Up Therapeutics in the future.
VectorBuilder’s Chief Scientist Bruce Lahn said, “VectorBuilder is very interested in Stand Up Therapeutics’s gene therapy for the treatment of paralysis at the global level. As a world leader in the design and GMP manufacturing of gene delivery vectors, I hope it would be a good opportunity for VectorBuilder to supply this product to Stand Up for patients worldwide.”
Stand Up Therapeutics CEO Dr. Junsang Yoo said, “Stand Up Therapeutics is the only one in the world that has the technology that treats paralyzed patients due to spinal cord injury using own developed direct cross differentiation technology (LYH-001). Members of Stand Up Therapeutics will work hard to develop a treatment for patients suffering from paralysis due to traumatic injury.” Also, “With the direct cross-differentiation PIPELINE technology, Stand Up Therapeutics plans to develop treatments for stroke (LYH-002), spinal muscular atrophy (LYH-003), spinal stenosis (LYH-004) and myocardial infarction (LYH-005) in the future.”
Today there are no approved therapies to prevent or reverse paraplegia, which affects nearly 1 in 50 people worldwide. Stand up Therapeutics is currently conducting the phase I and II clinical trials of LYH-001, a direct cross-differentiation drug. In pre-clinical trials, LYH-001 successfully treated paraplegia in the lumbar-5 spine injury animal model within 40 days.
This year, LYH-001 is scheduled to be administered for the treatment of Mr. Lee (34 years old), a patient who suffered an unexpected traffic accident at the Gonjiam Tunnel in 2019.
About Stand Up Therapeutics Co., Ltd.
Stand Up Therapeutics Co., Ltd. is a company that develops gene therapy of nerve cell regeneration using leading edge technology that converts fibroblasts into motor neurons in in vivo. Using the direct lineage reprogramming technique, a goal of Stand Up Therapeutics is to treat paralyzed patients due to spinal cord and brain injury and to relieve the suffering of mild and severe paralyzed patients of about 1.9% of the world’s population. Stand Up Therapeutics will serve the development of direct reprogramming technology and plan to expand the pipeline through R&D of safer and more efficient direct reprogramming methods and gene therapy.
For more information visit: stutps.com
About VectorBuilder Inc.
VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its proprietary Vector Design Studio is a transformative innovation that allows researchers to design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions, and state-of-the-art CDMO facilities. With leading R&D and GMP manufacturing capabilities, the VectorBuilder team aims to develop the most effective gene delivery tools for life sciences research and genetic medicine.